These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 29807243

  • 1. Combination of 7-hydroxycoumarin in a platinum(IV) complex derived from cisplatin enhanced cytotoxicity with multiple mechanisms of action.
    Hua W, Zhao J, Hu W, Gou S.
    J Inorg Biochem; 2018 Sep; 186():17-23. PubMed ID: 29807243
    [Abstract] [Full Text] [Related]

  • 2. Construction of Dual Stimuli-Responsive Platinum(IV) Hybrids with NQO1 Targeting Ability and Overcoming Cisplatin Resistance.
    Fang L, Qin X, Zhao J, Gou S.
    Inorg Chem; 2019 Feb 04; 58(3):2191-2200. PubMed ID: 30657321
    [Abstract] [Full Text] [Related]

  • 3. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
    Chen F, Qin X, Xu G, Gou S, Jin X.
    Biochem Pharmacol; 2017 Jul 01; 135():50-68. PubMed ID: 28288821
    [Abstract] [Full Text] [Related]

  • 4. Antitumor platinum(II) complexes of N-monoalkyl-1R, 2R-diaminocyclohexane derivatives with alkyl groups as hindrance.
    Sun Y, Yin R, Gou S, Zhaojian.
    J Inorg Biochem; 2012 Jul 01; 112():68-76. PubMed ID: 22561544
    [Abstract] [Full Text] [Related]

  • 5. Novel Pt(IV) complexes containing salvigenin ligand reverse cisplatin-induced resistance by inhibiting Rap1b-mediated cancer cell stemness in esophageal squamous cell carcinoma treatments.
    Zhao J, Wu K, Yang Y, Liu D, Zhang C, Li X.
    Bioorg Chem; 2024 Jun 01; 147():107384. PubMed ID: 38643568
    [Abstract] [Full Text] [Related]

  • 6. A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response.
    Chen F, Huang X, Wu M, Gou S, Hu W.
    Cancer Lett; 2017 Jan 28; 385():168-178. PubMed ID: 27793693
    [Abstract] [Full Text] [Related]

  • 7. Antitumor and cellular pharmacological properties of a novel platinum(IV) complex: trans-[PtCl(2)(OH)(2)(dimethylamine) (isopropylamine)].
    Pérez JM, Kelland LR, Montero EI, Boxall FE, Fuertes MA, Alonso C, Navarro-Ranninger C.
    Mol Pharmacol; 2003 Apr 28; 63(4):933-44. PubMed ID: 12644595
    [Abstract] [Full Text] [Related]

  • 8. Platinum(IV) complexes conjugated with chalcone analogs as dual targeting anticancer agents: In vitro and in vivo studies.
    Huang X, Liu Z, Wang M, Yin X, Wang Y, Dai L, Wang H.
    Bioorg Chem; 2020 Dec 28; 105():104430. PubMed ID: 33171407
    [Abstract] [Full Text] [Related]

  • 9. Design, synthesis and biological evaluation of a novel series of glycosylated platinum(iv) complexes as antitumor agents.
    Wang Q, Huang Z, Ma J, Lu X, Zhang L, Wang X, George Wang P.
    Dalton Trans; 2016 Jun 21; 45(25):10366-74. PubMed ID: 27252024
    [Abstract] [Full Text] [Related]

  • 10. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
    Ma ZY, Wang DB, Song XQ, Wu YG, Chen Q, Zhao CL, Li JY, Cheng SH, Xu JY.
    Eur J Med Chem; 2018 Sep 05; 157():1292-1299. PubMed ID: 30195239
    [Abstract] [Full Text] [Related]

  • 11. Synthesis of antitumor azolato-bridged dinuclear platinum(ii) complexes with in vivo antitumor efficacy and unique in vitro cytotoxicity profiles.
    Komeda S, Takayama H, Suzuki T, Odani A, Yamori T, Chikuma M.
    Metallomics; 2013 May 05; 5(5):461-8. PubMed ID: 23608770
    [Abstract] [Full Text] [Related]

  • 12. Naproxen platinum(iv) hybrids inhibiting cycloxygenases and matrix metalloproteinases and causing DNA damage: synthesis and biological evaluation as antitumor agents in vitro and in vivo.
    Chen Y, Wang Q, Li Z, Liu Z, Zhao Y, Zhang J, Liu M, Wang Z, Li D, Han J.
    Dalton Trans; 2020 Apr 28; 49(16):5192-5204. PubMed ID: 32236281
    [Abstract] [Full Text] [Related]

  • 13. Conjugation of platinum(IV) complexes with chlorambucil to overcome cisplatin resistance via a "joint action" mode toward DNA.
    Qin X, Fang L, Chen F, Gou S.
    Eur J Med Chem; 2017 Sep 08; 137():167-175. PubMed ID: 28586717
    [Abstract] [Full Text] [Related]

  • 14. Glycyrrhetinic Acid as a Hepatocyte Targeting Ligand-Functionalized Platinum(IV) Complexes for Hepatocellular Carcinoma Therapy and Overcoming Multidrug Resistance.
    Huang X, Li G, Li H, Zhong W, Jiang G, Cai J, Xiong Q, Wu C, Su K, Huang R, Xu S, Liu Z, Wang M, Wang H.
    J Med Chem; 2024 May 23; 67(10):8020-8042. PubMed ID: 38727048
    [Abstract] [Full Text] [Related]

  • 15. Mono-functionalized glycosylated platinum(IV) complexes possessed both pH and redox dual-responsive properties: Exhibited enhanced safety and preferentially accumulated in cancer cells in vitro and in vivo.
    Ma J, Yang X, Hao W, Huang Z, Wang X, Wang PG.
    Eur J Med Chem; 2017 Mar 10; 128():45-55. PubMed ID: 28147308
    [Abstract] [Full Text] [Related]

  • 16. Toward overcoming cisplatin resistance via sterically hindered platinum(II) complexes.
    Yu H, Gou S, Wang Z, Chen F, Fang L.
    Eur J Med Chem; 2016 May 23; 114():141-52. PubMed ID: 26974381
    [Abstract] [Full Text] [Related]

  • 17. Synthesis and evaluation of bi-functional 7-hydroxycoumarin platinum(IV) complexes as antitumor agents.
    Wang Q, Chen Y, Li G, Liu Z, Ma J, Liu M, Li D, Han J, Wang B.
    Bioorg Med Chem; 2019 May 15; 27(10):2112-2121. PubMed ID: 30981607
    [Abstract] [Full Text] [Related]

  • 18. Cellular and biomolecular responses of human ovarian cancer cells to cytostatic dinuclear platinum(II) complexes.
    Lin M, Wang X, Zhu J, Fan D, Zhang Y, Zhang J, Guo Z.
    Apoptosis; 2011 Mar 15; 16(3):288-300. PubMed ID: 21107699
    [Abstract] [Full Text] [Related]

  • 19. Antitumour and antiangiogenic activities of [Pt(O,O'-acac)(γ-acac)(DMS)] in a xenograft model of human renal cell carcinoma.
    Muscella A, Vetrugno C, Biagioni F, Calabriso N, Calierno MT, Fornai F, De Pascali SA, Marsigliante S, Fanizzi FP.
    Br J Pharmacol; 2016 Sep 15; 173(17):2633-44. PubMed ID: 27351124
    [Abstract] [Full Text] [Related]

  • 20. Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance.
    Huang X, Wang M, Wang C, Hu W, You Q, Yang Y, Yu C, Liao Z, Gou S, Wang H.
    Bioorg Chem; 2019 Nov 15; 92():103236. PubMed ID: 31494328
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.